Tarivd

Tarivid: Antimicrobial agent for effective fight against infections

Tarivid is a pharmacological drug from the group of antimicrobial agents belonging to the class of fluoroquinolones. Its international name is ofloxacin. The drug is produced in several countries, including India, Germany, Russia, Yugoslavia and Turkey.

Tarivid has a wide spectrum of action and is used to treat various infections. It is effective for severe respiratory tract infections such as pneumonia, lung abscess, bronchiectasis and exacerbation of bronchitis. In addition, the drug is used for infections of the ENT organs, skin and soft tissues, bones and joints, abdominal cavity, pelvic organs, kidneys, urinary tract, genital organs (including gonorrhea and prostatitis), chlamydial infections, septicemia, bacterial ulcers of the cornea and conjunctivitis. Tarivid is also used in the complex therapy of tuberculosis and for the prevention of infections in patients with immunodeficiency.

The drug is available in various dosage forms, including tablets, infusions and film-coated tablets. The main active ingredient of the drug is ofloxacin.

Like any medicine, Tarivid has contraindications and can cause side effects. The drug is not recommended for use in case of hypersensitivity to fluoroquinolones or quinolones, epilepsy, dysfunction of the central nervous system with a decrease in the threshold of convulsive readiness, during pregnancy, while breastfeeding and in children and adolescents under 18 years of age.

Possible side effects include dyspepsia, nausea, vomiting, diarrhea, anorexia, abdominal pain, dry mouth, pseudomembranous colitis, dizziness, headache, insomnia, anxiety, decreased reaction time, agitation, increased intracranial pressure, tremors, seizures, nightmares , hallucinations, psychosis, paresthesia, phobias, impaired coordination of movements, taste, smell, vision and diplopia. Disorders of color perception, loss of consciousness, and transient increases in bilirubin and liver enzymes in PlasTarivid: An antimicrobial agent for effective infection treatment may also occur.

Tarivid is a pharmacological drug that belongs to the class of fluoroquinolones, a group of antimicrobial agents. Its international nonproprietary name is ofloxacin. The drug is manufactured in several countries, including India, Germany, Russia, Yugoslavia, and Turkey.

Tarivid has a broad spectrum of activity and is used to treat various infections. It is effective in severe respiratory tract infections such as pneumonia, lung abscess, bronchiectasis, and exacerbations of bronchitis. Additionally, the drug is used for infections of the ENT organs, skin and soft tissues, bones and joints, abdominal cavity, pelvic organs, kidneys, urinary tract, genital organs (including gonorrhea and prostatitis), chlamydial infections, septicemia, bacterial corneal ulcers , and conjunctivitis. Tarivid is also used in the combination therapy of tuberculosis and for infection prophylaxis in immunocompromised patients.

The drug is available in various dosage forms, including tablets, infusion solutions, and film-coated tablets. The active ingredient of the medication is ofloxacin.

Like any medication, Tarivid has contraindications and can cause side effects. The drug is not recommended for individuals with hypersensitivity to fluoroquinolones or quinolones, epilepsy, central nervous system disorders with lowered seizure threshold, during pregnancy, breastfeeding, and in children and adolescents under 18 years of age.

Possible side effects include dyspepsia, nausea, vomiting, diarrhea, anorexia, abdominal pain, dry mouth, pseudomembranous colitis, dizziness, headache, insomnia, restlessness, decreased reaction speed, excitement, increased intracranial pressure, tremor, seizures, nightmares, hallucinations, psychosis, paresthesia, phobias, impaired coordination of movements, taste, smell, vision, and diplopia. Additionally, disturbances in color perception, loss of consciousness, transient elevation of bilirubin and liver enzymes in the blood may occur.